ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac surgery. But evidence for its use in non-cardiac surgery is still limited. 

ACC 2022 - Estudio POISE-3: Ácido tranexámico en pacientes sometidos a cirugía no cardíaca

The aim of this study was to assess whether tranexamic acid reduces the incidence of bleeding events, which include life threatening bleeding, major bleeding, or bleeding into a critical organ (superiority design) and MACE incidence assessment (non-inferiority design) at 30 days, compared against placebo. 

The study randomized 9535 patients, mean age 69, considered at risk of bleeding and cardiovascular events, 76.8% with non-orthopedic surgery. The dose of tranexamic acid was 1gr. both at the start and end of surgery. 

The use of tranexamic acid significantly reduced bleeding incidence (HR 0.76, CI95% 0.67-0.87, p.001), with no evidence of MACE reduction (HR 1.02, CI95% 092-1.14, p: 0.04) and without reaching non-inferiority.

Read also: STEMI: Can We Omit Stenting?

Within the adverse events there was higher risk of seizures (HR 3.35), with no significant differences in serious events (5.5% vs 5.1% p:0.16).

Conclusions 

In patients at risk of bleeding and cardiovascular events set to receive non-cardiac surgery, the use of tranexamic acid significantly reduces bleeding compared against placebo. Despite the low rate of MACE in both groups, non-inferiority was not reached for cardiovascular events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the editorial board, SOLACI.org

Original Title: Poise-3: Tranexamic Acid in Patients Undergoing Noncardiac Surgery

Reference: Devereaux, P. J., Marcucci, M., Painter, T. W., Conen, D., Lomivorotov, V., Sessler, D. I., Chan, M. T. V., Borges, F. K., Martínez-Zapata, M. J., Wang, C.-Y., Xavier, D., Ofori, S. N., Wang, M. K., Efremov, S., Landoni, G., Kleinlugtenbelt, Y. V., Szczeklik, W., Schmartz, D., Garg, A. X., … POISE-3 Investigators. (2022). Tranexamic acid in patients undergoing noncardiac surgery. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2201171


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...